Target Global Acquisition Stock (OTC: TGAWF)

Latest news for Target Global Acquisition (OTC:TGAWF) Stock

Target Global Acquisition I Corp is a blank check company.

Target Global Acquisition I Corp Warrants (09/03/2026)

Target Global Acquisition I Corp

Biotech

News

General

DRIO

CORRECTION: DarioHealth Entered Agreement With Blue Cross Blue Shield Was Announced On February 6, 2025

<p>Needham  analyst Bernie McTernan   reiterates Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) from Hold to Hold.</p>


Reiteration

Analyst Ratings

PTON

Needham Reiterates Hold on Peloton Interactiveto Hold

<p>Rosenblatt  analyst Catharine Trebnick   maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Buy and raises the price target from $115 to $125.</p>


Price Target

FTNT

Rosenblatt Maintains Buy on Fortinet, Raises Price Target to $125

<p>HC Wainwright &amp; Co.  analyst Mike Colonnese   reiterates Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) with a Buy and maintains $27 price target.</p>


CLSK

HC Wainwright & Co. Reiterates Buy on Cleanspark, Maintains $27 Price Target

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">103.6500</td>
<td align="right">0.69</td>
<td align="right">0.67</td>
<td>352</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">88.7400</td>
<td align="right">0.17</td>
<td align="right">0.19</td>
<td>12.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">137.9900</td>
<td align="right">0.25</td>
<td align="right">0.18</td>
<td>311</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.2700</td>
<td align="right">0.44</td>
<td align="right">0.18</td>
<td>3.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">89.5399</td>
<td align="right">0.16</td>
<td align="right">0.17</td>
<td>177</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">52.1800</td>
<td align="right">0.07</td>
<td align="right">0.13</td>
<td>152.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">228.74</td>
<td align="right">-1.34</td>
<td align="right">-0.59</td>
<td>4.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">78.22</td>
<td align="right">-0.08</td>
<td align="right">-0.11</td>
<td>348</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">79.42</td>
<td align="right">-0.05</td>
<td align="right">-0.07</td>
<td>331</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">147.07</td>
<td align="right">-0.05</td>
<td align="right">-0.04</td>
<td>2.2K</td>
</tr>
</tbody>
</table>
<p><a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. </p>
<p><em>For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.</em> </p>


Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For February 7, 2025

CYTH

Cyclo Therapeutics Presents Preliminary Data From Phase 3 TransportNPC Study Of Trappsol With 6 Of 7 Patients Showing Stabilization Or Improvement In Clinical Global Impression Over 48 Weeks; Topline 48-Week Interim Data Expected in H1 2025

<p>Needham  analyst Quinn Bolton   maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and raises the price target from $600 to $800.</p>


MPWR

Needham Maintains Buy on Monolithic Power Systems, Raises Price Target to $800

Guidance

BYRN

Byrna Says Well-Positioned To Generate Additional Cash And Expand Profitability In 2025 And Beyond

<p>Needham  analyst Quinn Bolton   maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $85 to $60.</p>


MCHP

Needham Maintains Buy on Microchip Technology, Lowers Price Target to $60

Byrna Expects Strong YoY Growth As It Continues Executing Strategic Initiatives, While Q1 Historically Experiences Seasonal Slowdown In Consumer Spending

<p>Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.10 by 310 percent.&nbsp;</p>


Earnings

Earnings Beats

Earnings Misses

Byrna Technologies Q4 2024 GAAP EPS $0.41 Beats $0.10 Estimate

<p>Northland Capital Markets  analyst Greg Gibas   maintains A-Mark Precious Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) with a Market Perform and lowers the price target from $40 to $36.</p>


AMRK

Northland Capital Markets Maintains Market Perform on A-Mark Precious Metals, Lowers Price Target to $36

ENFY

Enlightify Enters Cooperation Agreement With Huadian Gaintime Investment Fund Management Co. To Jointly Develop And Invest In Renewable Energy Projects

<p>Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent.  The company reported quarterly sales of $1.002 billion which beat the analyst consensus estimate of $984.071 million by 1.82 percent.  This is a 12.46 percent increase over sales of $891.000 million the same period last year.</p>


ULCC

Frontier Group Holdings Q4 2024 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.002B Beat $984.071M Estimate

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   reiterates Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy and maintains $50 price target.</p>


PTGX

HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $50 Price Target

<p> Palatin Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ptn#NYSE">PTN</a>) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the "Registered Direct Offering") at a purchase price of $1.00 per share. </p>


Penny Stocks

Offerings

Palatin Technologies Announces $4.7M Direct Offering Of 4.688M Shares Of Common Stock At A Price Of $1.00 Each

<p><i>Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio</i><br /><br />&nbsp;</p>
<p>NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=4YyVFRqflcXwGqhUPTu2VjFDGgtLwrW5VTXaIRFyk-IIIPuNlzUJ1jQBS1XGZkeW2u04U49EFMJDxbmDv53lI7G3RQd22H4wFDcieWxEMMdgqIbb8q9NPbI8fnx3Mbk4">Conduit Pharmaceuticals Inc. </a>(Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=ZTbTPPHxjU9RAGWKZNAxD9OEmTHgwAmSW93ya-3jDGJAoT_s17QSwtV023t8itckPH1PGyypdAhJgLcMBCOkJaQcs-63P0X8YmDPgL0iXJx3xZdGfHDatM_nKDvGX7dz7Ku1_yv2_IHuKXXf6ohNgLeoc5JQt7gupWXvm-x_9eb7n5iuRdTxyAAS0XEs3neoudqFzXxh_jB7kprIFCx9LQ4deVpkjll0AX-SQ0a7U-aMQzK0jJ0jkiPTYYdvTnPy">CDT)</a> ("<strong>Conduit</strong>" or the "<strong>Company</strong>"), today announces the successful completion of all milestones in Phase I of its strategic collaboration with Sarborg Limited. This transition to Phase II marks a positive step forward in Conduit's strategy to explore the integration advanced artificial intelligence (AI) and cybernetics into its drug development processes. With Phase I now complete, the Company is pleased to transition to Phase II, which will focus on the creation of personalized software dashboards to enhance operational efficiency and reporting.</p>
<p>The focus of Phase I was to establish a strong foundation for the collaboration with Sarborg, identify key inputs for the algorithmic approach, and align Sarborg's services with Conduit's strategic goals. The collaboration, initiated in December 2024, aims to revolutionize drug development by leveraging cutting-edge AI technologies to streamline drug repurposing, accelerate discovery, optimize solid-form identification, and enhance clinical trial monitoring. Phase I included teach-in sessions with management, the validation of Conduit's proprietary inputs that are critical for Sarborg's cybernetic models and, thirdly, a comprehensive market analysis of cocrystal candidates.</p>
<p>Conduit and Sarborg worked closely to align AI-driven processes with Conduit's portfolio needs, ensuring that proprietary inputs were tailored to maximize the potential of key assets, including AZD1656, AZD5904, AZD5658, CDT1656, and the AZD1656 cocrystals. Additionally, an in-depth market analysis of cocrystal candidates provided actionable insights into the competitive landscape, patent positioning, and market opportunities.</p>
<p>Conduit is now transitioning to Phase II, which is expected to focus on building the technological infrastructure necessary to support AI-driven drug development of its current and future portfolio of products. A key deliverable of this phase will be the creation of personalized software dashboards, designed to provide Conduit's key personnel with real-time access to critical data related to clinical trials, drug discovery, and portfolio management. These dashboards are designed to enable more agile and informed decision-making, allowing the Company to remain focused on delivering impactful clinical trials in autoimmune disorders.</p>


Conduit Pharmaceuticals Transitions To Phase II In Sarborg Collaboration For AI-Driven Drug Development; Phase II To Focus On Personalized Software Dashboards To Enhance Efficiency And Decision-Making

<p>Northland Capital Markets  analyst Tim Savageaux   maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Market Perform and raises the price target from $60 to $70.</p>


LITE

Northland Capital Markets Maintains Market Perform on Lumentum Holdings, Raises Price Target to $70

GAN Announces Extension Of End Date Of SEGA SAMMY Merger Agreement From Feb. 7 To May 31

<p>Rosenblatt  analyst Barton Crockett   maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Buy and raises the price target from $46 to $51.</p>


Comments

Target Global Acquisition

News

Latest news for Target Global Acquisition (OTC:TGAWF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga